Your browser doesn't support javascript.
loading
Asian-variant intravascular large B-cell lymphoma.
Su, Derrick W; Pasch, Whitney; Costales, Cristina; Siddiqi, Imran; Mohrbacher, Ann.
Afiliação
  • Su DW; Jane Anne Nohl Division of Hematology (Su, Mohrbacher) and the Hematopathology Section, Department of Pathology (Pasch, Costales), Norris Comprehensive Cancer Center and Hospital, University of Southern California, Los Angeles, California.
  • Pasch W; Jane Anne Nohl Division of Hematology (Su, Mohrbacher) and the Hematopathology Section, Department of Pathology (Pasch, Costales), Norris Comprehensive Cancer Center and Hospital, University of Southern California, Los Angeles, California.
  • Costales C; Jane Anne Nohl Division of Hematology (Su, Mohrbacher) and the Hematopathology Section, Department of Pathology (Pasch, Costales), Norris Comprehensive Cancer Center and Hospital, University of Southern California, Los Angeles, California.
  • Siddiqi I; Jane Anne Nohl Division of Hematology (Su, Mohrbacher) and the Hematopathology Section, Department of Pathology (Pasch, Costales), Norris Comprehensive Cancer Center and Hospital, University of Southern California, Los Angeles, California.
  • Mohrbacher A; Jane Anne Nohl Division of Hematology (Su, Mohrbacher) and the Hematopathology Section, Department of Pathology (Pasch, Costales), Norris Comprehensive Cancer Center and Hospital, University of Southern California, Los Angeles, California.
Proc (Bayl Univ Med Cent) ; 30(2): 186-189, 2017 Apr.
Article em En | MEDLINE | ID: mdl-28405077
ABSTRACT
Intravascular large B-cell lymphoma (IVLBCL) is a rare and deadly malignancy involving the growth of lymphoma cells within vessel lumina of all organ types. IVLBCL is further divided into the hemophagocytic Asian variant and a classical Western variant. Both variants are difficult to diagnose by imaging, and although diagnostic criteria have been developed to guide workup, histopathological examination remains imperative. Treatment of IVLBCL remains difficult given the high mortality of the disease, but rituximab has emerged as a promising therapeutic option when combined with various cytotoxic regimens. The two main variants of IVLBCL generally manifest in their respective Asian or Western populations, and crossover between ethnicities is rare. We present the second described case of Asian-variant IVLBCL in an African American individual.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article